Cargando…

Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer

SIMPLE SUMMARY: Immune checkpoint blockades (ICBs) to PD-L1 have led to major breakthroughs in cancer therapy, but in triple-negative breast cancer (TNBC) success rates are rather limited. Following studies suggesting that chronic inflammation may limit ICB efficacy, we found that pro-inflammatory c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baram, Tamir, Oren, Nino, Erlichman, Nofar, Meshel, Tsipi, Ben-Baruch, Adit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323351/ https://www.ncbi.nlm.nih.gov/pubmed/35884574 http://dx.doi.org/10.3390/cancers14143513

Ejemplares similares

Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes
por: Erlichman, Nofar, et al.
Publicado: (2022)

Correction: Erlichman et al. Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. Cancers 2022, 14, 1042
por: Erlichman, Nofar, et al.
Publicado: (2022)

The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
por: Erlichman, Nofar, et al.
Publicado: (2023)

Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors
por: Baram, Tamir, et al.
Publicado: (2021)

Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer
por: Liubomirski, Yulia, et al.
Publicado: (2019)

Co-Inflammatory Roles of TGFβ1 in the Presence of TNFα Drive a Pro-inflammatory Fate in Mesenchymal Stem Cells
por: Lerrer, Shalom, et al.
Publicado: (2017)

A Tumor Microenvironment-Driven Network Regulated by STAT3 and p65 Negatively Controls the Enrichment of Cancer Stem Cells in Human HR+/HER2− Breast Cancer
por: Ben-Yaakov, Hagar, et al.
Publicado: (2023)

Progression of Luminal Breast Tumors Is Promoted by Ménage à Trois between the Inflammatory Cytokine TNFα and the Hormonal and Growth-Supporting Arms of the Tumor Microenvironment
por: Weitzenfeld, Polina, et al.
Publicado: (2013)

Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells
por: Weitzenfeld, Polina, et al.
Publicado: (2016)

Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer
por: Liubomirski, Yulia, et al.
Publicado: (2019)

Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy
por: Morein, Dina, et al.
Publicado: (2020)

Continuous Inflammatory Stimulation Leads via Metabolic Plasticity to a Prometastatic Phenotype in Triple-Negative Breast Cancer Cells
por: Morein, Dina, et al.
Publicado: (2021)

Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy
por: Baram, Tamir, et al.
Publicado: (2021)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
por: Alkaabi, Duaa, et al.
Publicado: (2023)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells
por: Leibovich-Rivkin, Tal, et al.
Publicado: (2014)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
por: Barrett, Michael T., et al.
Publicado: (2018)

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
por: Chen, Xingyu, et al.
Publicado: (2022)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
por: Krueger, Kimberly, et al.
Publicado: (2022)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
por: Zhu, Xinxin, et al.
Publicado: (2017)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
por: Krueger, Kimberly, et al.
Publicado: (2022)

A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer
por: Wang, Chaoyang
Publicado: (2022)

Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis
por: Nakhjavani, Maryam, et al.
Publicado: (2022)

Tumor-Promoting Circuits That Regulate a Cancer-Related Chemokine Cluster: Dominance of Inflammatory Mediators Over Oncogenic Alterations
por: Leibovich-Rivkin, Tal, et al.
Publicado: (2012)

Breast Cancer: Coordinated Regulation of CCL2 Secretion by Intracellular Glycosaminoglycans and Chemokine Motifs()()
por: Lebel-Haziv, Yaeli, et al.
Publicado: (2014)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer
por: Li, Xuejiao, et al.
Publicado: (2022)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer
por: Imai, Yushi, et al.
Publicado: (2020)

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022)

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
por: Ren, Yifan, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
por: Mathias, Carolina, et al.
Publicado: (2023)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
por: Yajuk, Olga, et al.
Publicado: (2021)

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism
por: Raftery, Martin J., et al.
Publicado: (2018)

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
por: Nascimento, Catarina, et al.
Publicado: (2020)

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
por: Qiu, Yufan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ccpiio1aamf7593dh1mp9ar3lj